TY - JOUR T1 - Micro RNAs Promoting Growth and Metastasis in Preclinical <em>In Vivo</em> Models of Subcutaneous Melanoma JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 651 LP - 667 DO - 10.21873/cgp.20221 VL - 17 IS - 6 AU - ULRICH H. WEIDLE AU - SIMON AUSLĂ„NDER AU - ULRICH BRINKMANN Y1 - 2020/11/01 UR - http://cgp.iiarjournals.org/content/17/6/651.abstract N2 - During the last years a considerable therapeutic progress in melanoma patients with the RAF V600E mutation via RAF/MEK pathway inhibition and immuno-therapeutic modalities has been witnessed. However, the majority of patients relapse after therapy. Therefore, a deeper understanding of the pathways driving oncogenicity and metastasis of melanoma is of paramount importance. In this review, we summarize microRNAs modulating tumor growth, metastasis, or both, in preclinical melanoma-related in vivo models and possible clinical impact in melanoma patients as modalities and targets for treatment of melanoma. We have identified miR-199a (ApoE, DNAJ4), miR-7-5p (RelA), miR-98a (IL6), miR-219-5p (BCL2) and miR-365 (NRP1) as possible targets to be scrutinized in further target validation studies. ER -